"Anti-Allergic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
| Descriptor ID |
D018926
|
| MeSH Number(s) |
D27.505.954.016
|
| Concept/Terms |
Anti-Allergic Agents- Anti-Allergic Agents
- Agents, Anti-Allergic
- Anti Allergic Agents
- Anti-Allergy Drugs
- Anti Allergy Drugs
- Drugs, Anti-Allergy
- Antiallergy Agents
- Agents, Antiallergy
- Antiallergic Drugs
- Drugs, Antiallergic
- Antiallergics
- Anti-Allergics
- Anti Allergics
- Antiallergic Agents
- Agents, Antiallergic
|
Below are MeSH descriptors whose meaning is more general than "Anti-Allergic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Allergic Agents".
This graph shows the total number of publications written about "Anti-Allergic Agents" by people in this website by year, and whether "Anti-Allergic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 4 | 2 | 6 |
| 2009 | 1 | 1 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Allergic Agents" by people in Profiles.
-
McLaurin EB, Evans D, Repke CS, Sato MA, Gomes PJ, Reilly E, Blender N, Silva FQ, Vantipalli S, Metzinger JL, Gibson A, Goldstein MH. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. Am J Ophthalmol. 2021 09; 229:288-300.
-
Bielory L, Tabliago NRA. Flavonoid and cannabinoid impact on the ocular surface. Curr Opin Allergy Clin Immunol. 2020 10; 20(5):482-492.
-
Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020 08; 20(4):414-420.
-
Bielory L, Gross GN, Letierce A, Melas-Melt L, Lucio L. Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis. Ann Allergy Asthma Immunol. 2020 06; 124(6):616-621.e3.
-
Khan RS, Rizvi S, Syed BA, Bielory L. Current market trends in anterior ocular inflammatory disease landscape. Curr Opin Allergy Clin Immunol. 2019 10; 19(5):503-509.
-
Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, Grabher A, Swanson BN, Hamilton JD, Guillonneau S, Taniou C, Zhang D, Pirozzi G, Graham NMH, Staudinger H, Mannent LP, Khan A. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019 Sep - Oct; 7(7):2447-2449.e2.
-
Bielory L, Schoenberg D. Emerging Therapeutics for Ocular Surface Disease. Curr Allergy Asthma Rep. 2019 02 28; 19(3):16.
-
Pandit SA, Glass LRD. Non-glaucoma periocular allergic, atopic, and irritant dermatitis at an academic institution: A retrospective review. Orbit. 2019 Apr; 38(2):112-118.
-
Hadjokas NP, Reidy JJ, Farooq AV. Chronic Follicular Conjunctivitis in a Middle-aged Woman. JAMA Ophthalmol. 2018 07 01; 136(7):833-834.
-
Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Allergy Asthma Proc. 2018 Mar 01; 39(2):110-116.